Tsingke Biotech is a leader in synthetic biology, specializing in AI-driven molecular technologies to create world-class gene factories. We provide end-to-end services—from raw material production to GMP-grade nucleic acids—serving both research institutions and industrial enterprises.
Our AI-powered platform supports high-throughput oligonucleotide synthesis, antibody discovery and development, as well as strain engineering and screening. With over 20 years of experience, we have earned the trust of more than 300,000 clients worldwide, including academic institutions, biotech companies, diagnostic developers, and pharmaceutical manufacturers.
At Tsingke, we are committed to driving breakthroughs across research, diagnostics, and therapeutics. By streamlining R&D, production, and commercialization, we help partners turn discoveries into scalable, real-world solutions, fostering long-term growth in the industry.
Biotech for a Better World —Advancing scientific discovery through precision nucleic acid manufacturing.
The Great Tsingke Gene Factory — Building the world's most integrated and efficient platform for DNA/RNA synthesis.
Founded; commenced operations in nucleic acid synthesis
Founded; commenced operations in nucleic acid synthesis
Expanded into the production of chemical raw materials
Expanded into the production of chemical raw materials
Launched professional-grade gene sequencing services
Launched professional-grade gene sequencing services
Launched oligonucleotide synthesis and advanced modification services
Launched oligonucleotide synthesis and advanced modification services
Developed proprietary automated synthesizers and equipment
Developed proprietary automated synthesizers and equipment
Expanded into molecular reagent production
Expanded into molecular reagent production
Incorporated as Tsingke Biotechnology Co., Ltd.; specialized in high-throughput gene synthesis
Incorporated as Tsingke Biotechnology Co., Ltd.; specialized in high-throughput gene synthesis
Closed $21M Series A funding; expanded into the protein & antibody sector
Closed $21M Series A funding; expanded into the protein & antibody sector
Secured USD 56 million in Series B funding and launched R&D in gene regulation and small nucleic acid therapeutics
Secured USD 56 million in Series B funding and launched R&D in gene regulation and small nucleic acid therapeutics
Converted to a joint-stock company: Beijing Tsingke Biotech Co., Ltd.
Converted to a joint-stock company: Beijing Tsingke Biotech Co., Ltd.
Listed on the NEEQ
Listed on the NEEQ
Tsingke's operations are strategically distributed
across China to support the Gene Factory concept
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
